Mr. Mikael Silvennoinen has been the Chairman of the company since 2020. Prior to this, he served as an Executive in IMS Talent Oy since 2013. Prior to this, he served as a President and Chief Executive Officer, Chairman of the Executive Committee, Pohjola Bank Plc since 1997-2013. He also served as Member of the Executive Board, Head of Capital markets, Pohjola Bank Plc since 1997. Mr. Silvennoinen also served as the Head of Investment banking and International affairs, Pohjola Bank Plc. He also held position as a Head of private equity, Pohjola Bank Plc since 1989-1992 and Group treasurer, Wartsila Corporation and as a Finance Manager.

Ms. Liisa Hurme has been the President and Chief Executive Officer of the company since October 2022. Prior to this, he served as Senior Vice President, Global Operations. She also served as Chairman of the Board of Fermion Oy. Before this, she served as a Senior Vice President, Specialty Products since 2014-2018 . Prior to this, she served as a Senior Vice President, Proprietary Products since 2008-2013. Before this, she served as a Head of Urology and Oncology business since 2005-2007. She also held positions at Program Leader of pharmaceutical development projects for Hormonal and Urological therapies, Portfolio Manager, Project Manager and Researcher and Project Manager in Hormonal therapies.

Mr. Jari Karlson has been the Chief Financial Officer of the company since 2002. He is also serving as the member of the board of Tapiola Mutual Pension Insurance Company. Prior to these, he served as the Senior Vice President of Animal Health from 2010 to 2022 and as the Vice President of Orion Pharma from 2001 to 2002, Vice President, Finance of Kuusakoski Group Oy from 1999 to 2001, Controller, Director of planning for the Europe and Asia region and Director of Finance in Europe in Genencor International Inc., from 1990 to 1999. He also served as Financial Controller for the Biochem division in Cultor Oy from 1988 to 1989.